The Host Response in Patients with Sepsis Developing Intensive Care Unit–acquired Secondary Infections
- 15 August 2017
- journal article
- research article
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 196 (4) , 458-470
Abstract
Rationale: Sepsis can be complicated by secondary infections. We explored the possibility that patients with sepsis developing a secondary infection while in the intensive care unit (ICU) display sustained inflammatory, vascular, and procoagulant responses. Objectives: To compare systemic proinflammatory host responses in patients with sepsis who acquire a new infection with those who do not. Methods: Consecutive patients with sepsis with a length of ICU stay greater than 48 hours were prospectively analyzed for the development of ICU-acquired infections. Twenty host response biomarkers reflective of key pathways implicated in sepsis pathogenesis were measured during the first 4 days after ICU admission and at the day of an ICU-acquired infection or noninfectious complication. Measurements and Main Results: Of 1,237 admissions for sepsis (1,089 patients), 178 (14.4%) admissions were complicated by ICU-acquired infections (at Day 10 [6–13], median with interquartile range). Patients who developed a secondary infection showed higher disease severity scores and higher mortality up to 1 year than those who did not. Analyses of biomarkers in patients who later went on to develop secondary infections revealed a more dysregulated host response during the first 4 days after admission, as reflected by enhanced inflammation, stronger endothelial cell activation, a more disturbed vascular integrity, and evidence for enhanced coagulation activation. Host response reactions were similar at the time of ICU-acquired infectious or noninfectious complications. Conclusions: Patients with sepsis who developed an ICU-acquired infection showed a more dysregulated proinflammatory and vascular host response during the first 4 days of ICU admission than those who did not develop a secondary infection.Keywords
This publication has 35 references indexed in Scilit:
- Sepsis: a roadmap for future researchThe Lancet Infectious Diseases, 2015
- Severe Sepsis and Septic ShockNew England Journal of Medicine, 2013
- Effect of Eritoran, an Antagonist of MD2-TLR4, on Mortality in Patients With Severe SepsisJAMA, 2013
- Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approachThe Lancet Infectious Diseases, 2013
- Drotrecogin Alfa (Activated) in Adults with Septic ShockNew England Journal of Medicine, 2012
- Immunosuppression in Patients Who Die of Sepsis and Multiple Organ FailureJAMA, 2011
- The late phase of sepsis is characterized by an increased microbiological burden and death rateCritical Care, 2011
- Macroscopic Postmortem Findings in 235 Surgical Intensive Care Patients with SepsisAnesthesia & Analgesia, 2009
- Host–pathogen interactions in sepsisThe Lancet Infectious Diseases, 2008
- Efficacy and Safety of Tifacogin (Recombinant Tissue Factor Pathway Inhibitor) in Severe SepsisJAMA, 2003